Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-18 23:01 | 2025-09-16 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $24.34 | 5,000 | $121,700 | 118,730 |
| 2025-09-18 23:06 | 2025-09-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $2.81 | 7,046 | $19,785 | 474,862 |
| 2025-09-18 23:06 | 2025-09-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $2.80 | 6,267 | $17,573 | 393,670 |
| 2025-09-18 23:06 | 2025-09-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Director, Officer | SELL | $2.79 | 28,427 | $79,254 | 1,518,831 |
| 2025-09-18 23:31 | 2025-09-18 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $406.17 | 11,000 | $4,467,909 | 36,781 |
| 2025-09-18 23:30 | 2025-09-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $402.29 | 8,000 | $3,218,352 | 130 |
| 2025-09-18 23:45 | 2025-09-16 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $325.71 | 27,803 | $9,055,693 | 0 |
| 2025-09-17 23:15 | 2025-09-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $24.19 | 8,500 | $205,649 | 418,142 |
| 2025-09-18 00:01 | 2025-09-15 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | Officer | OPT+S | $11.49 | 15,829 | $181,875 | 0 |
| 2025-09-18 00:20 | 2025-09-17 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | Director, Officer | BUY | $2.02 | 2,500 | $5,050 | 1,140,937 |
| 2025-09-18 00:20 | 2025-09-16 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | Director, Officer | BUY | $1.97 | 2,600 | $5,122 | 290,659 |
| 2025-09-17 23:31 | 2025-09-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $79.08 | 27,000 | $2,135,055 | 249,062 |
| 2025-09-17 23:30 | 2025-09-15 | LQDA | Liquidia Corp | SINGH RAMAN | Director | OPT+S | $25.81 | 45,524 | $1,174,974 | 31,255 |
| 2025-09-17 23:45 | 2025-09-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $36.46 | 16,400 | $597,975 | 34,552 |
| 2025-09-18 01:06 | 2025-09-16 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% owner | SELL | $7.04 | 363,541 | $2,559,329 | 14,363,975 |
| 2025-09-17 23:03 | 2025-09-15 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | Officer | OPT+S | $41.41 | 15,000 | $621,143 | 97,130 |
| 2025-09-17 23:02 | 2025-09-15 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | OPT+S | $45.41 | 1,542 | $70,022 | 38,867 |
| 2025-09-18 02:39 | 2025-09-16 | MNKD | MANNKIND CORP | Tross Stuart A | Officer | SELL | $5.34 | 47,000 | $250,980 | 1,032,013 |
| 2025-09-18 02:00 | 2025-09-16 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | Officer | OPT+S | $114.48 | 45,783 | $5,241,128 | 0 |
| 2025-09-17 16:45 | 2025-09-15 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $2.68 | 3,400 | $9,105 | 81,650 |
| 2025-09-18 03:08 | 2025-09-15 | APLS | Apellis Pharmaceuticals Inc. | Chopas James George | Officer | SELL | $24.19 | 189 | $4,572 | 53,468 |
| 2025-09-18 00:22 | 2025-09-15 | NAMS | NewAmsterdam Pharma Co N.V. | Topper James N | Director | BUY | $23.70 | 660 | $15,639 | 3,028,524 |
| 2025-09-17 23:30 | 2025-09-16 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $400.27 | 4,000 | $1,601,062 | 130 |
| 2025-09-17 13:02 | 2025-09-15 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $400.56 | 22,500 | $9,012,625 | 0 |
| 2025-09-17 01:16 | 2025-09-16 | CNTA | Centessa Pharmaceuticals plc | Accardi Mario Alberto | Officer | SELL | $21.40 | 8,172 | $174,846 | 197,394 |
| 2025-09-17 01:06 | 2025-09-12 | ARWR | Arrowhead Pharmaceuticals Inc. | Hamilton James C | Officer | SELL | $30.00 | 15,000 | $450,000 | 232,122 |
| 2025-09-16 13:15 | 2025-09-15 | AARD | Aardvark Therapeutics, Inc. | Lee Tien-Li | Director, Officer, 10% owner | BUY | $9.66 | 10,000 | $96,624 | 1,543,384 |
| 2025-09-16 23:15 | 2025-09-12 | LBRX | LB PHARMACEUTICALS INC | Pontifax Management 4 G.P. (2015) Ltd. | 10% owner | BUY | $15.00 | 1,000,000 | $15,000,000 | 1,411,681 |
| 2025-09-17 01:54 | 2025-09-15 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | SELL | $36.00 | 11,367 | $409,265 | 81,524 |
| 2025-09-16 23:15 | 2025-09-12 | LBRX | LB PHARMACEUTICALS INC | Nussbaum Ran | Director | BUY | $15.00 | 1,000,000 | $15,000,000 | 1,411,681 |
| 2025-09-16 23:56 | 2025-09-12 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | OPT+S | $64.58 | 1,700 | $109,787 | 57,130 |
| 2025-09-16 23:35 | 2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Director, Officer | SELL | $6.43 | 1,257 | $8,083 | 84,046 |
| 2025-09-16 23:34 | 2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Mano Michael | Officer | SELL | $6.43 | 234 | $1,505 | 21,425 |
| 2025-09-16 23:33 | 2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | Officer | SELL | $6.43 | 401 | $2,578 | 27,710 |
| 2025-09-16 23:32 | 2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | Officer | SELL | $6.43 | 408 | $2,623 | 29,390 |
| 2025-09-16 23:31 | 2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Cheng Sohanya Roshan | Officer | SELL | $6.43 | 325 | $2,090 | 35,856 |
| 2025-09-16 23:30 | 2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Officer | SELL | $6.43 | 23 | $148 | 10,408 |
| 2025-09-17 02:45 | 2025-09-12 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.85 | 4,110 | $7,603 | 1,870,600 |
| 2025-09-17 01:09 | 2025-09-12 | LBRX | LB PHARMACEUTICALS INC | Deep Track Biotechnology Master Fund, Ltd. | 10% owner | BUY | $15.00 | 2,666,666 | $39,999,990 | 666,666 |
| 2025-09-17 04:45 | 2025-09-12 | CRMD | CorMedix Inc. | DUNTON ALAN W | Director | OPT+S | $13.13 | 10,000 | $131,300 | 40,250 |
| 2025-09-16 22:46 | 2025-09-12 | LBRX | LB PHARMACEUTICALS INC | Vida Ventures GP III, L.L.C. | 10% owner | BUY | $15.00 | 333,333 | $4,999,995 | 2,029 |
| 2025-09-16 23:15 | 2025-09-12 | ZVRA | ZEVRA THERAPEUTICS, INC. | FAVORITO TAMARA A | Director | BUY | $7.79 | 3,175 | $24,718 | 3,894 |
| 2025-09-17 02:36 | 2025-09-12 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $117.08 | 62,880 | $7,361,890 | 7,229 |
| 2025-09-16 14:44 | 2025-09-12 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $400.93 | 8,000 | $3,207,436 | 130 |
| 2025-09-17 01:00 | 2025-09-15 | ACAD | Acadia Pharmaceuticals Inc. | Schneyer Mark C. | Officer | SELL | $23.65 | 3,498 | $82,728 | 43,447 |
| 2025-09-17 00:00 | 2025-09-11 | PTCT | PTC THERAPEUTICS, INC. | Reeve Emma | Director | OPT+S | $59.50 | 15,705 | $934,448 | 10,332 |
| 2025-09-16 01:37 | 2025-09-15 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $21.85 | 6,000 | $131,101 | 105,386 |
| 2025-09-16 03:12 | 2025-09-11 | CAMP | Camp4 Therapeutics Corp | 5AM Partners VI, LLC | 10% owner | BUY | $1.53 | 2,941,176 | $4,499,999 | 2,941,176 |
| 2025-09-15 23:05 | 2025-09-12 | RAPP | Rapport Therapeutics, Inc. | Huber Reid M | Director | BUY | $24.48 | 20,400 | $499,374 | 20,400 |
| 2025-09-15 19:31 | 2025-09-12 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $3.12 | 5,000 | $15,600 | 78,250 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.